Esperion Therapeutics to Present at Barclays Global Healthcare Conference
Esperion Therapeutics to Present at Barclays Global Healthcare Conference
March 3, 2015
A live, listen-only webcast of the presentation can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the presentation will be available approximately one hour after completion and will be archived on the Company's website for 90 days following the event.
Esperion's Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two preclinical product candidates.
About
FOR FURTHER INFORMATION PLEASE CONTACT:
Media Contact:Elliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact:Mindy Lowe Esperion Therapeutics, Inc. 734.887.3903 mlowe@esperion.com Source:Esperion Therapeutics, Inc.
News Provided by Acquire Media